NTT Launches IoT Services for Sustainability
NTT Ltd., a global technology and business solutions provider, today announced the launch of its IoT Services for Sustainability offering. The new end-to-end stack of solutions will help businesses advance progress against global sustainability initiatives and make data-driven decisions to reduce their carbon footprint through the intelligent use of IoT connectivity.
These solutions include:
- OCR Meter Reading: An optical-based meter reader to provide near real-time data from any type of meter including water, electricity, and gas. The meter can also be used to read any type of gauge including pressure and temperature.
- Water Leak Management: This technology provides real-time, IoT enabled protection against water damage for smart spaces projects.
- Predictive Maintenance: This solution collects data from sensors to create models that predict when events of interest might occur, including potential downtime, accidents or when something might need to be replaced.
- Environmental Monitoring: This technology uses sensors to identify the presence of pollutants in the air and water as well as tracking temperature and humidity.
NTT’s IoT Services for Sustainability stack incorporates a secure IT/OT integration and end-to-end support. This helps organizations to quickly see the benefits of the technology across the entire business following deployment. Benefits include energy cost savings, faster reduction in emissions, advanced operational excellence, and better work enablement across the organization. The stack of solutions is also supported by NTT’s new LoRaWAN network, and its catalog of sensors to measure, monitor and collect data to drive sustainability objectives.
“IoT technologies are an essential tool in the global fight against climate change,” said Jeff Merritt, Head of Urban Transformation at the World Economic Forum. “We know what actions are needed to build a more sustainable future and have a robust suite of technologies available to help deliver this impact. As the world looks to accelerate the implementation of these solutions, organizations like NTT will have a critical role to play in helping companies and governments capitalize on this opportunity.”
This announcement follows the appointment of two industry veterans to drive growth and momentum across NTT’s IoT and sustainability initiatives. Wireless industry leader Devin Yaung has been appointed as SVP of Group Enterprise IoT Products and Services, NTT Ltd., bringing over 25 years of technology experience focused on business transformation. Vicky Bullivant has also been appointed as Senior Vice President, Group Sustainability, NTT Ltd. Vicky has 25 years of creating and delivering successful sustainability, social, climate and ESG strategies that underpin commercial objectives in fast-paced and evolving business environments.
"Almost two-thirds (61.4%) of CEOs say they’re aligning business strategies to the UN’s Sustainable Development Goals. Yet only 2 out of 5 businesses have the solutions needed to meet the organization's immediate objectives,” said Devin Yaung, SVP of Group Enterprise IoT Products and Services.
"Therefore, it is more critical than ever to prioritize and deliver sustainability solutions for our enterprise customers. Our new stack of solutions will help organizations reach their sustainability goals and improve operations across their business, whether it is reducing waste from manufacturing defects or understanding the carbon footprint of their supply chain. The use of IoT will empower businesses to make decisions in real-time, streamlining processes and transforming the overall sustainability of their business. We’re proud to be announcing this offering at such a critical time, and we look forward to driving change alongside our clients to create a more sustainable future."
To find out more about NTT’s IoT Services for Sustainability solutions, please visit here.
About NTT Ltd.
NTT Ltd. is a leading, global technology services company. To help our clients achieve their digital transformation goals, we use our global capabilities, expertise, and full-stack technology services delivered through our integrated services platform. As their long-term strategic partner, we help them enhance customer and employee experience, transform their cloud strategy, modernize their networks and strengthen their cybersecurity. And across their transformation priorities, we automate their business processes and IT, drawing insights and analytics from their core business data. As a global ICT provider, we employ more than 50,000 people across 57 countries, trading in 73 countries and delivering services in over 200 countries and regions. Together we enable the connected future.
Visit us at services.global.ntt
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005090/en/
Contact information
Media Inquiries:
Hotwire for NTT Ltd.
Hannah Lock
NTT@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom